March 21, 2018 / 12:09 PM / a month ago

BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin

Reuters Staff

1 Min Read

March 21 (Reuters) - Cidara Therapeutics Inc:

* CIDARA THERAPEUTICS PROVIDES CLINICAL DATA UPDATES FOR ITS LEAD ANTIFUNGAL REZAFUNGIN

* CIDARA THERAPEUTICS - ADDITIONAL DATA AND ANALYSES FROM STRIVE PHASE 2 CLINICAL TRIAL CONFIRM POSITIVE EFFICACY RESULTS IN BOTH REZAFUNGIN ARMS Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.